Isbn: 9781617796944 - mtor pathway and mtor inhibitors in cancer therapy (cancer drug discovery and development) (10 resultados)

ISBN
Refinar con la Búsqueda avanzada

Filtrar la búsqueda

  • Libros (10)

  • Nuevo (10)

a

Intervalo de precios personalizado (EUR)

a

  • Idioma: Inglés

    Editorial: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda

    Librería: Ria Christie Collections, Uxbridge, Reino UnidoRia Christie Collections

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 227,07

    Envío por EUR 13,17 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New. In English.

  • Más imágenes

    Idioma: Inglés

    Editorial: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda

    Librería: preigu, Osnabrück, Alemaniapreigu

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 184,95

    Envío por EUR 70,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 5 disponibles

    Taschenbuch. Condición: Neu. mTOR Pathway and mTOR Inhibitors in Cancer Therapy | Vitaly A. Polunovsky (u. a.) | Taschenbuch | Cancer Drug Discovery and Development | xii | Englisch | 2012 | Humana | EAN 9781617796944 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

  • Idioma: Inglés

    Editorial: Humana Press Inc., 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda

    Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 251,96

    Envío por EUR 9,50 
    Se envía de Irlanda a Estados Unidos de America

    Cantidad disponible: 15 disponibles

    Condición: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . .

  • Idioma: Inglés

    Editorial: Humana Press, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda

    Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 304,51

    Envío por EUR 11,66 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Paperback. Condición: Brand New. 316 pages. 9.25x6.10x0.75 inches. In Stock.

  • Idioma: Inglés

    Editorial: Humana Press Inc., 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda

    Librería: Kennys Bookstore, Olney, MD, Estados Unidos de AmericaKennys Bookstore

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 318,29

    Envío por EUR 9,14 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 15 disponibles

    Condición: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . . Books ship from the US and Ireland.

  • Idioma: Inglés

    Editorial: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda
    • Impresión bajo demanda

    Librería: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 166,29

    Envío por EUR 5,50 
    Se envía de Italia a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: new. Questo è un articolo print on demand.

  • Idioma: Inglés

    Editorial: Humana Press, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda
    • Impresión bajo demanda

    Librería: moluna, Greven, Alemaniamoluna

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 180,07

    Envío por EUR 48,99 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding .

  • Idioma: Inglés

    Editorial: Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda
    • Impresión bajo demanda

    Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AlemaniaBuchWeltWeit Ludwig Meier e.K.

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 213,99

    Envío por EUR 23,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics. 316 pp. Englisch.

  • Idioma: Inglés

    Editorial: Humana Press, Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda
    • Impresión bajo demanda

    Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemaniabuchversandmimpf2000

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 213,99

    Envío por EUR 60,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 316 pp. Englisch.

  • Idioma: Inglés

    Editorial: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 de 96 - Cancer Drug Discovery and Development

    • Tapa blanda
    • Impresión bajo demanda

    Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 297,68

    Envío por EUR 30,50 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.